Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related ( ATR ) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer

Although many patients with colorectal cancer initially respond to the chemotherapeutic agent oxaliplatin, acquired resistance to this treatment remains a major challenge to the long-term management of this disease. To identify molecular targets of oxaliplatin resistance in colorectal cancer, we per...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Jg. 79; H. 11; S. 2933
Hauptverfasser:	Combès, Eve, Andrade, Augusto F, Tosi, Diego, Michaud, Henri-Alexandre, Coquel, Flavie, Garambois, Veronique, Desigaud, Delphine, Jarlier, Marta, Coquelle, Arnaud, Pasero, Philippe, Bonnefoy, Nathalie, Moreaux, Jerome, Martineau, Pierre, Del Rio, Maguy, Beijersbergen, Roderick L, Vezzio-Vie, Nadia, Gongora, Celine
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.06.2019
Schlagworte:	Animals Antineoplastic Agents - pharmacology Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis - drug effects Apoptosis - genetics Ataxia Telangiectasia Mutated Proteins - antagonists & inhibitors Ataxia Telangiectasia Mutated Proteins - genetics Cell Line, Tumor Checkpoint Kinase 2 - metabolism Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - immunology DNA Breaks, Double-Stranded - drug effects Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Female Humans Isoxazoles - administration & dosage Isoxazoles - pharmacology Mice, Inbred C57BL Oxaliplatin - administration & dosage Oxaliplatin - pharmacology Pyrazines - administration & dosage Pyrazines - pharmacology T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - pathology Xenograft Model Antitumor Assays
ISSN:	1538-7445, 1538-7445
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!